The Claim
In high-risk cardiovascular patients, administration of inclisiran at doses of 284mg or 300mg results in a reduction of low-density lipoprotein cholesterol (LDL-c) by 54.83% and 43.11%, respectively, compared to placebo, after a median of 24 weeks, demonstrating a potent and durable lipid-lowering effect with twice-yearly dosing.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A shot called inclisiran can cut bad cholesterol by more than half in people at high risk for heart problems, and it works with just two doses a year.
See the scientific wording
Inclisiran, administered at 284mg or 300mg, reduces low-density lipoprotein cholesterol (LDL-c) by 54.83% and 43.11% respectively compared to placebo after a median of 24 weeks in high-risk cardiovascular patients, demonstrating a potent and durable lipid-lowering effect with twice-yearly dosing.
What the research says
1 studyThe study looked at the same drug and doses mentioned in the claim and found they lowered bad cholesterol by the exact amounts said, so the claim is backed by the evidence.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.